Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts

American Journal of Cardiology

Volumn 84, Issue 4 SUPPL. 1, 1999, Pages 27-33

  Zhang, Xiaoping ^a   Kichuk, Maryanne R ^b   Mital, Seema ^b   Oz, Mehmet ^b   Michler, Robert ^b   Nasjletti, Alberto ^a   Kaley, Gabor ^a   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Division of Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ICATIBANT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHORAMIDON; RAMIPRILAT; THIORPHAN; BRADYKININ; BRADYKININ RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; GLYCOPEPTIDE; METALLOPROTEINASE; NITRITE; QUININE; RAMIPRIL; SERINE PROTEINASE INHIBITOR; KININ; PHOSPHORAMIDIC ACID DERIVATIVE;

ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART FAILURE; HUMAN; HUMAN TISSUE; ISOLATED HEART; METHODOLOGY; MICROVASCULATURE; PRIORITY JOURNAL; VASODILATATION; BIOSYNTHESIS; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FORWARD HEART FAILURE; METABOLISM; MICROCIRCULATION; CONFERENCE PAPER; DRUG EFFICACY;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CALCIUM CHANNEL BLOCKERS; CARDIAC OUTPUT, LOW; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPEPTIDES; HUMANS; METALLOENDOPEPTIDASES; MICROCIRCULATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITES; QUININE; RAMIPRIL; RECEPTORS, BRADYKININ; SERINE PROTEINASE INHIBITORS; THIORPHAN;

EID: 0033584293     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00362-8     Document Type: Article

References (32)

1. Lliceto S. Left ventricular dysfunction which role for calcium antagonists? Eur Heart J. 18:(suppl A):1997;A87-A91.
2. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
3. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberg G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Effects of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
4. Zhang X.P., Hintze H.T. Amlodipine releases nitric oxide from canine coronary microvessels an unexpected mechanism of action of a calcium channel blocking agent . Circulation. 97:1998;576-580.
5. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide, physiology, pathophysiology and pharmacology. Pharmacol Rev. 43:1991;109-142.
6. Treasure C.B., Vita J.A., Cox D.A., Fish R.D., Gordon J.B., Mudge G.H., Colucci W.S., St. John Sutton M.G., Selwyn A.P., Alexander R.W., Ganz P. Endothelium-dependent dilation of coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 81:1990;772-779.
7. Katz S.D., Schwarz M., Yuen J., Lejemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure role of endothelium-derived vasodilating and vasoconstricting factors . Circulation. 88:1993;55-61.
8. Drexler H., Hayoz D., Munzel T., Just H., Zelis R., Brunner H.R. Endothelial dysfunction in chronic heart failure experimental and clinical studies . Arzneimittelforschung. 44:(suppl I):1994;455-458.
9. Kubo S.H., Rector T.S., Bank A.J., William R.E., Heifetz S.M. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 84:1991;1589-1596.
10. Zhang X., Xie Y., Nasjletti A., Xu X., Wolin M.S., Hintze H.T. ACE inhibitors stimulate nitric oxide production to modulate myocardial oxygen consumption. Circulation. 95:1997;176-182.
11. Zhang X, Nasjletti A, Xu X, Hintze TH. Neutral endopeptidase and angiotensin converting enzyme modulate nitric oxide production in coronary microvessels via a kinin-dependent mechanism. J Cardiovasc Pharmacol 1998;31:623-629.
12. Gerritsen M.E., Printz M.P. Sites of prostaglandin synthesis in the bovine heart and isolated bovine coronary microvessels. Circ Res. 49:1981;1152-1163.
13. Elkayam U., Amin J., Mehra A., Vasquez J., Weber L., Rahimtoola S.H. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 82:1990;1954-1961.
14. Baron J.N., Rouleau J.-L., Bichet D., Juneau C., De Champlain J. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol. 9:1987;622-630.
15. Goldstein R.E., Boccuzzi S.J., Gruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 83:1991;52-60.
16. Tan L.B., Murray R.G., Littler W.A. Felodipine in patients with chronic heart failure discrepant hemodynamic and clinical effects . Br Heart J. 58:1987;122-128.
17. Littler W.A., Sheridan D.J. Placebo controlled trial of felodipine in patients with mild to moderate heart failure UK Study Group . Br Heart J. 73:1995;428-433.
18. Remme W.J. Neurohormonal modulation in heart failure ACE inhibition and beyond . Eur Heart J. 16:(suppl N):1995;73-78.
19. Seymour A.A., Asaad M., Lanoce V.M., Langenbacher K.M., Fennell S.A., Rogers W.L. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther. 266:1993;872-883.
20. Wiemer G., Scholkens B.A., Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 28:1994;166-172.
21. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular action of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
22. Kichuk M.R., Zhang X.P., Oz M., Michler R., Kaley G., Nasjletti A., Hintze T.H. Angiotensin converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human heart. Am J Cardiol. 80:(suppl):1997;137A-142A.
23. Ura N., Shimamoto K., Nomura N., Aoyama T., Iwata M., Takagawa Y., Iimura O. The mechanism of the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens. 17:1995;1183-1196.
24. Taylor S.H. A review of amlodipine in myocardial ischemia. Postgrad Med J. 67:(suppl 5):1991;S48-S51.
25. Dodd M.G., Gardiner D.G., Carter A.J., Sutton M.R., Burges R.A. The hemodynamic properties of amlodipine in anesthetized and conscious dogs comparison with nitrendipine and influence of beta-adrenergic blockade . Cardiovasc Drugs Ther. 3:1989;545-555.
26. Lyons D., Webster J., Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial N-monomethyl-L-arginine in patients with essential hypertension. J Hypertens. 12:1994;1047-1052.
27. Mugge A., Peterson T., Harrison D.G. Release of nitrogen oxides from cultured bovine aortic endothelial cells is not impaired by calcium channel antagonists. Circulation. 83:1991;1404-1409.
28. 2+ and stimulates prostaglandin synthesis by cultured bovine aortic endothelial cells. Horm Metab Res. 29:1997;38-42.
29. 2+ channels. Br J Pharmacol. 117:1996;1035-1040.
30. Trippodo N.C., Fox M., Natarajan V., Panchal B.C., Dorso C.R., Asaad M.M. Combination of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther. 267:1993;108-116.
31. Messerli F.H., Michalewicz L. Cardiac effects of combination therapy. Am J Hypertens. 10:1997;146S-152S.
32. Mohler J. III, Sorensen L.C., Ghali J.K., Schoken D.D., Willis P.W., Bowers J.A., Cropp A.B., Pressler M.L. Role of cytokines in the mechanism of action of amlodipine the PRAISE heart failure trial . J Am Coll Cardiol. 30:1997;35-41.